CareDx (CDNA) Tops Q3 EPS by 51c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
CareDx Reports Third Quarter 2016 Financial Results
November 9, 2016 4:01 PM ESTBRISBANE, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financial results for the third quarter ended September 30, 2016.
Recent highlights:
Achieved total revenue for the third quarter of 2016 of $12.5M, up 74% year-over-year AlloMap® revenues were $8.6M in the quarter, with US tests volume up by 6% year-over-yearOlerup® revenues contributed $3.8M in the third quarter Launched Olerup... More